Cutaneous manifestations of diabetes mellitus

Clinical Diabetes

Volumn 33, Issue 1, 2015, Pages 40-48

  Duff, Michelle ^a   Demidova, Olga ^b   Blackburn, Stephanie ^a   Shubrook, Jay ^b  

^a OhioHealth   (United States)

^b OHIO UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTOCONAZOLE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CLOTRIMAZOLE; CORTICOSTEROID; CRYSTAL VIOLET; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; PSORALEN; TERBINAFINE; TIOCONAZOLE;

ACANTHOSIS NIGRICANS; ACROCHORDONS; ARTICLE; BULLOSIS DIABETICORUM; CANDIDIASIS; CUTANEOUS PERFORATING DISORDER; DERMATOPHYTOSIS; DIABETES MELLITUS; DIABETIC DERMOPATHY; EPIDERMOLYSIS; GRANULOMA ANNULARE; HUMAN; INTERTRIGO; LICHEN PLANUS; NAIL DYSTROPHY; NECROBIOSIS LIPOIDICA; NON INSULIN DEPENDENT DIABETES MELLITUS; ONYCHOMYCOSIS; PARONYCHIA; PERIUNGUAL TELANGECTASIA; PSORIASIS; RUBEOSIS FACEI; SCLEREDERMA DIABETICORUM; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; THRUSH; TINEA PEDIS; VITILIGO; VULVOVAGINITIS; XANTHOMA; XEROSIS;

EID: 84921810540     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.33.1.40     Document Type: Article

References (68)

1. Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet. Available from http://www.cdc. gov/DIABETES//pubs/factsheet11.htm. Accessed 25 August 2013
2. Demirseren DD, Emre S, Akoglu G, et al. Relationship between skin diseases and extracutaneous complications of diabetes mellitus: clinical analysis of 750 patients. Am J Clin Dermatol 2014;15:65-70
3. Kalus AA, Chien AJ, Olerud JE. Chapter 151: Diabetes mellitus and other endocrine diseases. In Fitzpatrick's Dermatology in General Medicine. 8th ed. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, Eds. New York, McGraw- Hill, 2012. Available online from http:// accessmedicine.mhmedical.com/content. aspx?bookid=392§ionid=41138874. Accessed 11 November 2014
4. Hud JA Jr, Cohen JB, Wagner JM, Cruz PD Jr. Prevalence and significance of acanthosis nigricans in an adult obese population. Arch Dermatol 1992;128:941-944
5. Stuart CA, Pate CJ, Peters EJ. Prevalence of acanthosis nigricans in an unselected population. Am J Med 1989;87:269-272
6. Banik R, Lubach D. Skin tags: localization and frequencies according to sex and age. Dermatologica 1987;174:180-183
7. Brickman WJ, Huang J, Silverman BL, Metzger BE. Acanthosis nigricans identifies youth at high risk for metabolic abnormalities. J Pediatr 2010;156:87-92
8. Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet M. Skin tags: a cutaneous marker for diabetes mellitus. Acta Dermato-Venereologica 1987;67:175-177
9. Ko CJ. Dermal hypertrophies and benign fibroblastic/myofibroblastic tumors. In Fitzpatrick's Dermatology in General Medicine. 8th ed. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Lefferr DJ, Wolf K, Eds. New York, McGraw-Hill, 2012. Available from http://accessmedicine. mhmedical.com/content.aspx?bookid=392§ionid=41138766. Accessed 11 November 2014
10. Ragunatha S, Anitha B, Inamadar AC, Palit A, Devarmani SS. Cutaneous disorders in 500 diabetic patients attending diabetic clinic. Indian J Dermatol 2011;56:160-164
11. McCash S, Emanuel PO. Defining diabetic dermopathy. J Dermatol 2011;38:988-992
12. Paron NG, Lambert PW. Cutaneous manifestations of diabetes mellitus. Prim Care 2000;27:371-383
13. Martínez DP, Díaz JÓF, Bobes CM. Eruptive xanthomas and acute pancreatitis in a patient with hypertriglyceridemia. Int Arch Med 2008;1:6
14. Binić I, Janković A. Eruptive xanthomas associated with diabetes mellitus. Chin Med J 2009;122:2074-2075
15. Levy L, Zeichner JA. Dermatologic manifestation of diabetes. J Diabetes 2012;4:68-76
16. Ferringer T, Miller F 3rd. Cutaneous manifestations of diabetes mellitus. Dermatol Clin 2002;20:483-492
17. Namazi MR, Jorizzo JL, Fallahzadeh MK. Rubeosis faciei diabeticorum: a common, but often unnoticed, clinical manifestation of diabetes mellitus. ScientificWorldJournal 2010;10:70-71
18. Gitelson S, Wertheimer-Kaplinski N. Color of the face in diabetes mellitus: observations on a group of patients in Jerusalem. Diabetes 1965;14:201-208
19. Tabor CA, Parlette EC. Cutaneous manifestations of diabetes. Postgrad Med 2006;119:38-44
20. Chan HL, Stern RS, Arndt KA, et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990;126:43-47
21. Rzany B, Mockenhaupt M, Baur S, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769-773
22. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of sixty cases. J Am Acad Dermatol 1985;13:623-635
23. Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. P T 2010;35:509-513
24. Valeyrie-Allanore L, Roujeau J. Epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis). In Fitzpatrick's Dermatology in General Medicine. 8th ed. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, Eds. New York, McGraw-Hill, 2012. Available from http://accessmedicine. mhmedical.com/content.aspx?bookid=392§ionid=41138737. Accessed 11 November 2014
25. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child 1922;24:526-533
26. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges 2009;7:142-160
27. Paquet P, Nikkels A, Arrese JE, Vanderkelen A, Piérard GE. Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis. Arch Dermatol 1994;130:605-608
28. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 2010;88:60-68
29. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285
30. Januvia [package insert]. Whitehouse Station, NJ, Merck & Co., 2010
31. Ellis MW, Oster CN, Turiansky GW, Blanchard JR. A case report and a proposed algorithm for the transfer of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis to a burn center. Mil Med 2002;167:701-704
32. Kota SK, Jammula S, Kota SK, Meher LK, Modi KD. Necrobiosis lipoidica diabeticorum: a case-based review of literature. Indian J Endocrinol Metab 2012;16:614-620
33. Lowitt MH, Dover JS. Necrobiosis lipoidica. J Am Acad Dermatol 1991;25:735-748
34. O'Toole EA, Kennedy U, Nolan JJ, Young MM, Roger S, Barnes L. Necrobiosis lipoidica: only a minority of patients have diabetes mellitus. Br J Dermatol 1999;140:283-286
35. Roy S, Shayaan M. Unsightly rash on shin. necrobiosis lipoidica diabeticorum. J Fam Pract 2012;61:215-217
36. Cohen O, Yaniv R, Karasik A, Trau H. Necrobiosis lipoidica and diabetic control revisited. Med Hypotheses 1996;46:348-350
37. Hann SK, Park YK, Chun WH. Clinical features of vitiligo. Clin Dermatol 1997;15:891-897
38. Spritz R. The genetics of generalized vitiligo. Curr Dir Autoimmun 2008;10:244-257
39. Mahajan S, Koranne R, Sharma S. Cutaneous manifestation of diabetes melitus. Indian J Dermatol Venereol Leprol 2003;69:105-108
40. Birlea SA, Spritz RA, Norris DA. Chapter 74: Vitiligo. In Fitzpatrick's Dermatology in General Medicine. 8th ed. Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, Eds. New York, McGraw-Hill, 2012. Available from http://accessmedicine.mhmedical.com/content.aspx?bookid=392§ionid=41138776. Accessed 11 Nomveber 2014
41. Lipsky BA, Baker PD, Ahroni JH. Diabetic bullae: 12 cases of a purportedly rare cutaneous disorder. Int J Dermatol 2000;39:196-200
42. Romano G, Moretti G, Di Benedetto A, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract 1998;39:101-107
43. Khalid U, Hansen PR, Gislason G, et al. Psoriasis is associated with increased risk of incident diabetes mellitus: a Danish nationwide cohort study. Eur Heart J 2012;33:360-361
44. Richards H, Fortune D, O'Sullivan T, Main C, Griffiths C. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-583
45. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001;26:343-350
46. Puri N. A study on cutaneous manifestations of diabetes mellitus. Our Dermatology Online 2012;3:87
47. Le Cleach L, Chosidow O. Lichen planus. N Engl J Med 2012;366:723-732
48. Wagner G, Rose C, Sachse MM. Clinical variants of lichen planus. J Dtsch Dermatol Ges 2013;11:309-319
49. Lehman JS, Tollefson MM, Gibson LE. Lichen planus. Int J Dermatol 2009;48:682-694
50. Goyal A, Raina S, Kaushal SS, Mahajan V, Sharma NL. Pattern of cutaneous manifestation in diabetes mellitus. Indian J Dermatol 2010;55:39-41
51. Cole GW, Headley J, Skowsky R. Scleredema diabeticorum: a common and distinct cutaneous manifestation of diabetes mellitus. Diabetes Care 1983;6:189-192
52. Thumpimukvatana N, Wongpraparut C, Lim HW. Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy. J Dermatol 2010;37:1036-1039
53. Van Hattem S, Bootsma AH, Thio HB. Skin manifestations of diabetes. Cleve Clin J Med 2008;75:772-782
54. Sahin MT, Türel-Ermertcan A, Oztürkcan S, Türkdogan P. Generalized granuloma annulare in a patient with type II diabetes mellitus: successful treatment with isotretinoin. J Eur Acad Dermatol Venereol 2006;20:111-114
55. Struder E, Calza A, Saurat J. Precipitating factors and associated disorders in 84 patients with granuloma annulare: a retrospective study. Dermatology 1996;193:364-368
56. Dabski K, Winkelmann R. Generalized granuloma annulare: clinical and laboratory findings in 100 patients. J Am Acad Dermatol 1989;20:30-47
57. Cyr PR. Diagnosis and management of granuloma annulare. Am Fam Phys 2006;74:1729-1734
58. Arroyo MP. Generalized granuloma annulare. Dermatol Online J 2003;9:13
59. Farrell A. Commentary: acquired perforating dermatosis in renal and diabetic patients. Lancet 1997;349:895-896
60. Maurice P, Neild GH. Acquired perforating dermatosis and diabetic nephropathy: a case report and review of the literature. Clin Exp Dermatol 1997;22:291-294
61. Mutluoglu M, Uzun G, Karabacak E. Toenail onychodystrophy of the diabetic foot. BMJ Case Rep 2012 Oct. 19;2012
62. Millikan LE, Powell DW, Drake LA. Quality of life for patients with onychomycosis. Int J Dermatol 1999;38(Suppl. 2):13-16
63. Landau J, Davis E. The small blood vessels of the conjunctiva and nail bed in diabetes mellitus. Lancet 1960;2:731-734
64. Romano C, Massai L, Asta F, et al. Prevalence of dermatophytic skin and nail infections in diabetic patients. Mycoses 2001;44:83-86
65. Higa M. Clinical epidemiology of fungal infection in diabetes. Nihon Rinsho 2008;66:2239-2244
66. Qadim HH, Golforoushan F, Azimi H, Goldust M. Factor leading to dermatophytosis. Ann Parisitol 2013;59:99-102
67. Yeung C, Lee K. Community acquired fulminant pseudomonas infection of the gastrointestinal tract in previously healthy infants. J Paediatr Child Health 1998;34:584-587
68. Soheilipour S, Meidani M, Derakhshandi H, et al. Necrotizing external otitis: a case series. B-ENT 2013;9:61-66